Brief Title
Fresh Corneal Lenticule Implantation in Macular Corneal Distrophy With Relex Smile Surgery
Official Title
Fresh Corneal Lenticule Implantation in Macular Corneal Distrophy With Relex-Smile Surgery
Brief Summary
The aim of the study is to examine the effect of fresh corneal lenticule implantation as allogenic graft taken from myopic patients to implanted in patients with macular corneal dystrophy using Visumax Femtosecond Laser Smile module surgery.
Detailed Description
Macular Corneal Dystrophy is a severe form of stromal corneal dystrophy characterized by bilateral cloudy regions within hazy stroma and eventually severe visual impairment. Most cases of MCD are caused by mutations in the CHST6 gene encoding a protein involved in the production of keratan sulfate, which plays a role in the maintenance of corneal transparency. According to biomechanical instability of corneal metabolism (abnormal increase collagenase activity, decrease proteinase inhibitors, excessive premature keratocyte apoptosis, increase cytokine binding) at corneal dystrophies. Fresh Corneal Lenticule and autologous serum contains live stem cells that produce keratocytes, collagen fibers, extracellular matrix which contribute to the regeneration of the cornea, and all this results at increasing of corneal transparency and visual acuity in patients with corneal macular dystrophy.
Study Type
Interventional
Primary Outcome
Increase of corneal transparency
Secondary Outcome
Increase of visual acuity
Condition
Macular Corneal Dystrophy
Intervention
Fresh Corneal Lenticule Implantation using Relex-Smile Surgery
Study Arms / Comparison Groups
ReLex Smile surgery
Description: The myopic lenticule after Relex Smile surgery is put into BBS solution for 10 min. Under topical anesthesia, Using VisuMax Femtosecond Laser.
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Procedure
Estimated Enrollment
10
Start Date
June 1, 2019
Completion Date
June 1, 2022
Primary Completion Date
June 1, 2020
Eligibility Criteria
Inclusion Criteria: - indications for penetrating keratoplasty - low transparec of corneae - low visual acuity Exclusion Criteria: - active anterior segment pathology - previous corneal or anterior segment surgery - any infection
Gender
All
Ages
20 Years - 55 Years
Accepts Healthy Volunteers
No
Contacts
, ,
Location Countries
Kosovo
Location Countries
Kosovo
Administrative Informations
NCT ID
NCT04642729
Organization ID
EyeHP
Responsible Party
Principal Investigator
Study Sponsor
Eye Hospital Pristina Kosovo
Study Sponsor
, ,
Verification Date
November 2020